Lexidronam

Lexidronam (also known as Samarium-153 lexidronam) is a radioactive pharmaceutical agent used in the treatment of pain associated with metastatic bone disease. It is a type of radiopharmaceutical that is used in palliative care for patients with certain types of cancer.

Overview

Lexidronam is a radioisotope of the element samarium, specifically Samarium-153. It is combined with a drug known as EDTMP (ethylenediaminetetramethylenephosphonate) to form Samarium-153 EDTMP, which is the active ingredient in lexidronam.

Mechanism of Action

Lexidronam works by delivering a high dose of radiation directly to the bones. The drug is designed to target areas of the bone where cancer has spread, delivering a lethal dose of radiation to the cancer cells while sparing the surrounding healthy tissue. This is achieved through the use of the EDTMP molecule, which has a high affinity for bone tissue, particularly areas of increased bone turnover such as those seen in metastatic bone disease.

Uses

Lexidronam is primarily used in the treatment of pain associated with metastatic bone disease. It can be used in patients with various types of cancer, including breast cancer, prostate cancer, and lung cancer, among others. It is typically used in cases where the pain has not responded to more conventional treatments.

Side Effects

Like all medications, lexidronam can cause side effects. The most common side effects include nausea, vomiting, and diarrhea. Less common side effects can include a decrease in blood cell counts, which can lead to an increased risk of infection, bleeding, and anemia.

See Also

• Radiopharmaceutical
• Palliative care
• Metastatic bone disease